Loading...

TRAW TRAWS PHARMA INC US FDA Inspections 8-K Filing

TRWS

TRW

TRAWS PHARMA INC

(TRAW)

2025 8-K

Show Summary

Show Summary

Clinical Trials

Pre-Market Approval

Corporate Presentation

Financial Statements

Management Changes

Earnings Announcement

Management Changes

COVID-19 Treatment Data

Positive Study Results

Positive Study Results

Compliance Update

Capital Structure Update

Stockholder Meeting

Nasdaq Compliance

Management Changes

Phase 1 Completion

Securities Offering

Partnership Announcement

Partnership Announcement

Product Launch Plans

Earnings Report

Other Special Situation

Filing with Quantitative Data

Financial Results

Other Special Situation

Financial Update

Financial Update

Other Special Situation

Filing with Quantitative Data

Other Special Situation

Financial Update

Management Changes

Clinical Development Update

Clinical Development Update

External Links:

On June 3, 2025, Traws Pharma, Inc. announced clinical data showing an 80% overall response rate in patients treated with rigosertib for advanced squamous cell carcinoma, with 50% achieving complete responses. The company also posted presentations re

AI Assistant

TRAWS PHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.